No abstract

We estimate the seroprevalence of IgG antibodies to varicella zoster virus (VZV) based on the first serological study in a cohort of pregnant women and newborns from the Aburrá Valley (Antioquia-Colombia) who attended delivery in eight randomly chosen hospitals. An indirect enzyme immunoassay was used to determine anti-VZV IgG antibodies. Generalized linear models were constructed to identify variables that modify seropositivity. In pregnant women, seropositivity was 85.8% (95% CI: 83.4–85.9), seronegativity was 12.6% (95% CI: 10.8–14.6), and concordance with umbilical cord titers was 90.0% (95% CI: 89–91). The seropositivity of pregnant women was lower in those who lived in rural areas (IRR: 0.4, 95% CI: 0.2–0.7), belonged to the high socioeconomic status (IRR: 0.4, 95% CI: 0.2–0.7), and had studied 11 years or more (IRR: 0.6, 95% CI: 0.4–0.8). Among newborns, seropositivity was lower in those who weighed less than 3000 g (IRR: 0.8, 95% CI: 0.6–1.0). The high seropositivity and seronegativity pattern indicates the urgent need to design preconception consultation and vaccination reinforcement for women of childbearing age according to their sociodemographic conditions, to prevent infection and complications in the mother and newborn.

No abstract

(RCOG). High-risk patients were defined as a Padua score of 4, Caprini 2, and RCOG 2. Three different cutoffs were analyzed for the Caprini RAM. The primary outcome was VTE occurring during delivery or up to 1 year postpartum. We calculated the proportion of women who would have been high risk, determined the number of VTE cases within high and low risk category, as well as calculated the number needed to treat (NNT) for each RAM. We performed sensitivity analyses using different cutoffs for the RAM scores, upper limit of VTE risk, and different efficacy of anticoagulation to prevent VTE. RESULTS: A total of 6158 women were included. The overall rate of VTE was 0.05%, 95% CI (0.01-0.15). The proportion of women categorized at high risk for VTE were 62% for RCOG, 0.8% for Padua, and 94% for Caprini (Table 1). There were no differences in the rates between the high and low risk for any of the RAMs (Table 1). The observed NNT assuming 100% efficacy of thromboprophylaxis was 3838 for RCOG, not able to calculate for Padua and 1927 for Caprini (Table 2). For the best-case scenario (using upper limit of VTE rate and 100% efficacy) the NNT was 1000 for RCOG, 14 for Padua and 1000 for Caprini (Table 2). NNTs for additional scenarios are provided in Table 2. CONCLUSION: The rates of VTE in pregnancy are very low and the available RAMs do not identify most of them. The RCOG and Caprini RAMs would categorize a large proportion of women as high risk and are associated with high NNTs. The Padua RAM appears to have the lowest NNT but failed to identify all VTEs in the study.